WO1996017249A1 - Spongiform encephalopathy detection methods - Google Patents
Spongiform encephalopathy detection methods Download PDFInfo
- Publication number
- WO1996017249A1 WO1996017249A1 PCT/GB1995/002766 GB9502766W WO9617249A1 WO 1996017249 A1 WO1996017249 A1 WO 1996017249A1 GB 9502766 W GB9502766 W GB 9502766W WO 9617249 A1 WO9617249 A1 WO 9617249A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- animal
- spongiform encephalopathy
- body fluid
- amount
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Definitions
- the present invention relates to methods for the detection of spongiform encephalopathies in animals, and in particular for the detection of bovine spongiform encephalopathy (BSE) in cattle.
- BSE bovine spongiform encephalopathy
- Spongiform encephalopathies are a group of diseases which include scrapie in sheep and Creutzfeldt-Jakob disease (CJD) in humans.
- BSE is a notifiable fatal neurodegenerative disease found in cattle. BSE is of major importance to the British farming industry.
- Cases of BSE are identified by clinical manifestations in the animal. Cases are confirmed by post-mortem analysis of brain tissue, for instance by histopathology, by detection of scrapie associated fibrils or proteinase K resistant protein.
- the present invention has now provided a method for detecting spongiform encephalopathies in animals which addresses some, and in preferred forms all, of these problems.
- a method for detecting the presence of spongiform encephalopathy in an animal comprising determining the presence and/or amount of agent in a body fluid of the animal which cross-reacts with antibody raised against apoliprotein E, and relating the result of this determination to the infection status of the animal.
- the result of the determination is compared with a control value, and the relationship between the two is correlated with the infection status of the animal.
- the method is used to detect BSE.
- Apolipoprotein E is a cholesterol transporting protein produced in the peripheral and central nervous system. Its presence in either multiple- or single-forms has been categorised in cerebrospinal fluid (CSF) and serum.
- CSF cerebrospinal fluid
- agent or agents are cross reactive with anti-apolipoprotein E, have a molecular weight of around 34-38 kDa, and have a pi of around 5-4 - 5-7- This is consistent with their identification as apolipoprotein E, and the term 'Apo E agent' as used hereinafter is intended to embrace any agent which has these properties (including apolipoprotein E itself and isoforms or multiple-forms thereof).
- the control value may be derived from the Apo E agent concentration in a different animal (for which the infection status is known) and which is analysed in parallel with the test animal.
- the control value may come from the same animal, or be a known standard.
- the control value may be determined using the same method used for the test animal, or may be derived by a different analytical method.
- the results from the 'control' animal may be used to derive a standard positive- or negative-control value, or to calibrate the test animal result.
- the body fluid analysed in the method is CSF since authentic apolipoprotein E is the major apolipoprotein found in this fluid.
- the proximity of the CSF to brain means that neurological disorders which produce alterations in the protein composition of the brain may be manifested in the CSF.
- Methods for extracting samples of CSF are well known to those skilled in the art.
- the invention embraces any method for analysing the concentration of Apo E agent in a body fluid of an animal which is currently comprised in the art, and any methods which may later become available.
- the presence and/or amount of Apo E agent in a body fluid of the animal is derived by the use of PAGE or 2DPAGE to separate out the Apo E agent from other agents in the body fluid, and then staining the gel and making densitometry measurements in the region of the gel of interest in order to determine the presence and/or amount of the Apo E agent.
- the identity of the Apo E agent is confirmed by use of immunogenic material, for instance antibody raised against Apo E agent or a synthetic peptide based on a sequence thereof.
- immunogenic material for instance antibody raised against Apo E agent or a synthetic peptide based on a sequence thereof.
- Suitable immunogen-based techniques for identifying the presence of cross-reactive agents are well known to those skilled in the art eg. ELISA or Western Blotting.
- these immunogenic techniques may be used both to identify the Apo E agent, and also to estimate its concentration.
- the invention makes available methods for detecting the presence of spongiform encephalopathy in a test animal which address many, and in preferred forms all, of the problems of the prior art.
- the balance between test certainty and ease of use will be dependent on the precise method of Apo E agent analysis chosen for use in the methods of the current invention.
- the pre-mortem diagnosis of BSE in cattle opens up the possibility of mass-testing in herds, thereby reducing the likelihood of slaughtering uninfected animals or 'missing' infected ones.
- Sample preparation CSF samples were collected from BSE-positive cattle and BSE-negative cattle. In each case the diagnosis was confirmed by post-mortem histopathology and electron microscopy. CSF samples were taken by cisternamagna puncture after death and concentrated 10-15 fold. Volumes of CSF containing 40 ⁇ g total protein were mixed in a 4:1 ratio with denaturing solution (lg sodium dodecyl sulphate (SDS) and 0.232g dithiothreitol in 10ml water) and heated at 95°C for 5 minutes. Samples were then pulse centrifuged.
- denaturing solution lg sodium dodecyl sulphate (SDS) and 0.232g dithiothreitol in 10ml water
- Electrophoresis The prepared samples were 2D electrophoresed using a Millipore Investigator 2D electrophoresis system according to the method in the instruction manual. First dimensional iso-electric-focussing was carried out in 26 cm threaded glass tubes with 1 mm inner diameter in a pH gradient of 3 _ 10 for 18000 volt hours after pre-focussing the gels for 1 hour to 1500 V. Second dimension SDS-PAGE was carried out using 1 mm thick large format gels (23 cm x 23 cm) with 12 .5% acrylamide and no stacking gel. Staining and Image analysis: The 2D gels were silver stained according to the Millipore manual. Gels were scanned with an O ⁇ -nimedia scanner XRS and analysed using Bioimage software and Investigator Database programme (Millipore) using a sunSPARC station computer.
- Comparison of BSE-negative and BSE-positive cattle A comparison of the stained gels from typical BSE-positive and -negative samples is shown in Fig 1(a) and Fig 1(b). As can be seen the number and intensity of the silver stained spots in the region corresponding to agents having an approximate molecular weight of 34-38 kDa, and a pi of around 5.4 - 5-7 (labelled 'Apo E' ) is higher in the BSE-positive sample.
Abstract
A method for detecting the presence of spongiform encephalopathy in an animal comprising determining the presence and/or amount of agent (e.g. by the use of 2DPAGE, followed by staining and densitometry readings of the stained agent) in a body fluid (e.g. cerebrospinal fluid) of test animal which cross-reacts with antibody raised against apoliprotein E, and has a molecular weight of between 34 and 38 kDa and a pI of between 5.4 and 5.7 comparing the concentration with a control value, and correlating the relationship between the two with the likely presence of spongiform encephalopathy in the animal.
Description
SPQNGIFORM ENCEPHALOPATHY DETECTION METHODS
The present invention relates to methods for the detection of spongiform encephalopathies in animals, and in particular for the detection of bovine spongiform encephalopathy (BSE) in cattle.
Spongiform encephalopathies are a group of diseases which include scrapie in sheep and Creutzfeldt-Jakob disease (CJD) in humans.
BSE is a notifiable fatal neurodegenerative disease found in cattle. BSE is of major importance to the British farming industry.
Currently cases of BSE are identified by clinical manifestations in the animal. Cases are confirmed by post-mortem analysis of brain tissue, for instance by histopathology, by detection of scrapie associated fibrils or proteinase K resistant protein.
These methods have the disadvantage that they necessitate the slaughter of potentially-infected animals which may turn out to be disease-free. Alternatively, clinical signs may be absent or go undetected, thus leaving infected animals in the herd.
Harrington e_r_ al (New England Journal of Medicine (1986) Vol 315. No 5, pp 279-283) used high resolution two dimensional polyacrylamide gel electrophoresis (2DPAGE) to discover the presence of 4 abnormal proteins in the cerobrospinal fluid of human patients suffering from CJD. However, the precise identity of these proteins was not ascertained.
Thus there exists a need for a pre-mortem test for spongiform encephalopathies which can be used when diagnosing potentially-infected animals.
The present invention has now provided a method for detecting spongiform encephalopathies in animals which addresses some, and in preferred forms all, of these problems.
According to one aspect of the present invention there is provided a method for detecting the presence of spongiform encephalopathy in an animal comprising determining the presence and/or amount of agent in a body fluid of the animal which cross-reacts with antibody raised against apoliprotein E, and relating the result of this determination to the infection status of the animal.
Preferably the result of the determination is compared with a control value, and the relationship between the two is correlated with the infection status of the animal.
Preferably the method is used to detect BSE.
Apolipoprotein E is a cholesterol transporting protein produced in the peripheral and central nervous system. Its presence in either multiple- or single-forms has been categorised in cerebrospinal fluid (CSF) and serum.
Thus the discovery that spongiform encephalopathy infection in an animal can be correlated with the presence of, or an increase in the concentration of, an agent or agents in the body fluids of that animal, forms the basis for the methods of the current invention.
The agent or agents are cross reactive with anti-apolipoprotein E, have a molecular weight of around 34-38 kDa, and have a pi of around 5-4 - 5-7- This is consistent with their identification as apolipoprotein E, and the term 'Apo E agent' as used hereinafter is intended to embrace any agent which has these properties (including apolipoprotein E itself and isoforms or multiple-forms thereof).
It should be noted that there is no requirement to accurately quantify the Apo E agent concentration because spongiform encephalopathy may be detected by comparison with a control.
The control value may be derived from the Apo E agent concentration in a different animal (for which the infection status is known) and which is analysed in parallel with the test animal. Alternatively,
the control value may come from the same animal, or be a known standard.
The control value may be determined using the same method used for the test animal, or may be derived by a different analytical method.
The results from the 'control' animal may be used to derive a standard positive- or negative-control value, or to calibrate the test animal result.
Preferably the body fluid analysed in the method is CSF since authentic apolipoprotein E is the major apolipoprotein found in this fluid. Additionally, the proximity of the CSF to brain means that neurological disorders which produce alterations in the protein composition of the brain may be manifested in the CSF. Methods for extracting samples of CSF are well known to those skilled in the art.
The invention embraces any method for analysing the concentration of Apo E agent in a body fluid of an animal which is currently comprised in the art, and any methods which may later become available.
Preferably the presence and/or amount of Apo E agent in a body fluid of the animal is derived by the use of PAGE or 2DPAGE to separate out the Apo E agent from other agents in the body fluid, and then staining the gel and making densitometry measurements in the region of the gel of interest in order to determine the presence and/or amount of the Apo E agent.
Preferably the identity of the Apo E agent is confirmed by use of immunogenic material, for instance antibody raised against Apo E agent or a synthetic peptide based on a sequence thereof. Suitable immunogen-based techniques for identifying the presence of cross-reactive agents are well known to those skilled in the art eg. ELISA or Western Blotting.
In alternative embodiments of the invention, these immunogenic techniques may be used both to identify the Apo E agent, and
also to estimate its concentration.
Thus the invention makes available methods for detecting the presence of spongiform encephalopathy in a test animal which address many, and in preferred forms all, of the problems of the prior art. The balance between test certainty and ease of use will be dependent on the precise method of Apo E agent analysis chosen for use in the methods of the current invention. However, the pre-mortem diagnosis of BSE in cattle opens up the possibility of mass-testing in herds, thereby reducing the likelihood of slaughtering uninfected animals or 'missing' infected ones.
The methods of the present invention will now be described, by way of illustration only, through reference to the following example and figures. Other embodiments falling within the scope of the invention will occur to those skilled in the art in the light of this.
EXAMPLE - IDENTIFICATION OF BSE IN CATTLE
Sample preparation: CSF samples were collected from BSE-positive cattle and BSE-negative cattle. In each case the diagnosis was confirmed by post-mortem histopathology and electron microscopy. CSF samples were taken by cisternamagna puncture after death and concentrated 10-15 fold. Volumes of CSF containing 40 μg total protein were mixed in a 4:1 ratio with denaturing solution (lg sodium dodecyl sulphate (SDS) and 0.232g dithiothreitol in 10ml water) and heated at 95°C for 5 minutes. Samples were then pulse centrifuged.
Electrophoresis: The prepared samples were 2D electrophoresed using a Millipore Investigator 2D electrophoresis system according to the method in the instruction manual. First dimensional iso-electric-focussing was carried out in 26 cm threaded glass tubes with 1 mm inner diameter in a pH gradient of 3_10 for 18000 volt hours after pre-focussing the gels for 1 hour to 1500 V. Second dimension SDS-PAGE was carried out using 1 mm thick large format gels (23 cm x 23 cm) with 12 .5% acrylamide and no stacking gel.
Staining and Image analysis: The 2D gels were silver stained according to the Millipore manual. Gels were scanned with an Oπ-nimedia scanner XRS and analysed using Bioimage software and Investigator Database programme (Millipore) using a sunSPARC station computer.
Confirmation of the identity of Apo E agent: The 2D gels were electroblotted onto Immobilon-P membranes overnight at 30V using a Bio-Rad Trans-Blot cell. The blots were blocked using Tween 80 for 1 hour and then incubated for 90 minutes with sheep antiserum containing polyclonal antibody raised against authentic apolipoprotein E. Bound sheep antibodies were detected using rabbit anti-sheep IgG and a horseradish peroxidase detection system. A number of agents in the region of interest (approximate molecular weight of 34-38 kDa, and a pi of around 5-4 - 5-7) were found to have cross reacted with anti-apolipoprotein E antibody.
Comparison of BSE-negative and BSE-positive cattle: A comparison of the stained gels from typical BSE-positive and -negative samples is shown in Fig 1(a) and Fig 1(b). As can be seen the number and intensity of the silver stained spots in the region corresponding to agents having an approximate molecular weight of 34-38 kDa, and a pi of around 5.4 - 5-7 (labelled 'Apo E' ) is higher in the BSE-positive sample.
A comparison of the mean optical density of those silver-stained spots on the gels which were also found to cross react with anti-apolipoprotein E antibody is found below:
Agent ------ BSE-negative BSE-Dositive
1 0.13 0.47
2 0.42 0.84
3 0.45 0.64
4 0.45 0.99
5 0.46 1.02
6 0.4l 0.69
7 0.87 1.12
By comparing the two sets of optical density readings it can be seen that each agent is present in consistently higher amounts in the BSE-positive (n=31) animals than in the BSE-negative (n=27) animals, thus indicating that the presence and/or amount of these agents can be used to detect the likely presence of BSE in potentially infected animals.
Claims
1. A method for detecting the presence of spongiform encephalopathy in an animal comprising determining the presence and/or amount of agent in a body fluid of the animal which cross-reacts with antibody raised against apoliprotein E, and relating the result of this determination to the infection status of the animal.
2. A method as claimed in claim 1 wherein the result of the determination is compared with a control value, and the relationship between the two is correlated with the infection status of the animal.
3- A method as claimed in claim 1 or claim 2 wherein the agent has a molecular weight of between 34 and 38 kDa and a pi of between 5-4 and 5-7
4. A method as claimed in any one of the preceding claims wherein the agent is apolipoprotein E.
5. A method as claimed in any one of the preceding claims wherein the spongiform encephalopathy is bovine spongiform encephalopathy.
6. A method as claimed in any one of the preceding claims wherein the body fluid analysed in the method is cerebrospinal fluid.
7. A method as claimed in any one of the preceding claims wherein the presence and/or amount of agent in a body fluid of the animal is determined by substantially separating the agent from other materials in the body fluid of the animal using polyacryla ide gel electrophoresis, staining the gel, identifying the agent, and determining the presence and/or amount of the agent from the density of the staining of the agent.
8. A method as claimed in claim 7 wherein the polyacrylamide gel electrophoresis is two-dimensional polyacrylamide gel electrophoresis.
9. A method as claimed in any one of the preceding claims wherein the identity of the agent is confirmed by use of immunogenic material.
10. A method as claimed in any one of claims 1 to 6 wherein the presence and/or amount of agent in a body fluid of the animal is determined by by the use of immunogenic material.
11. A method as claimed in claim 9 or 10 wherein the immunogenic material is antibody raised against apolipoprotein E.
12. A method as claimed in any one of claims 2 to 11 wherein the control value is derived by the same method as that used with the animal but using a further animal known to be either spongiform encephalopathy-negative or -positive.
13. A method for detecting the presence of spongiform encephalopathy in an animal substantially as described hereinbefore.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ295721A NZ295721A (en) | 1994-11-29 | 1995-11-28 | Detection of antibodies to spongiform encephalopathy |
| GB9708663A GB2308659B (en) | 1994-11-29 | 1995-11-28 | Spongiform encephalopathy detection methods |
| AU39328/95A AU3932895A (en) | 1994-11-29 | 1995-11-28 | Spongiform encephalopathy detection methods |
| SK678-97A SK67897A3 (en) | 1994-11-29 | 1995-11-28 | Spongiform encephalopathy detection methods |
| CZ971642A CZ164297A3 (en) | 1994-11-29 | 1995-11-28 | Method of detecting spongy-like encephalopathy |
| EP95937124A EP0795132A1 (en) | 1994-11-29 | 1995-11-28 | Spongiform encephalopathy detection methods |
| NO972339A NO972339D0 (en) | 1994-11-29 | 1997-05-22 | Methods for detecting spongiform encephalopathy |
| FI972253A FI972253A (en) | 1994-11-29 | 1997-05-28 | Detection procedure for fungal brain disease |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9424015A GB9424015D0 (en) | 1994-11-29 | 1994-11-29 | Spongiform encepmalopathy detection methods |
| GB9424015.7 | 1994-11-29 | ||
| GBGB9424769.9A GB9424769D0 (en) | 1994-11-29 | 1994-12-07 | Spongiform encephalopathy detection methods |
| GB9424769.9 | 1994-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996017249A1 true WO1996017249A1 (en) | 1996-06-06 |
Family
ID=26306057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1995/002766 WO1996017249A1 (en) | 1994-11-29 | 1995-11-28 | Spongiform encephalopathy detection methods |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0795132A1 (en) |
| AU (1) | AU3932895A (en) |
| CA (1) | CA2205179A1 (en) |
| CZ (1) | CZ164297A3 (en) |
| FI (1) | FI972253A (en) |
| GB (1) | GB2308659B (en) |
| HU (1) | HUT77340A (en) |
| NO (1) | NO972339D0 (en) |
| NZ (1) | NZ295721A (en) |
| SK (1) | SK67897A3 (en) |
| WO (1) | WO1996017249A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016834A1 (en) | 1996-10-15 | 1998-04-23 | Imperial College Of Science, Technology And Medicine | Diagnosis of spongiform encephalopathy |
| EP0854364A1 (en) * | 1997-01-18 | 1998-07-22 | Harash Kumar Narang | Diagnosis of neuro-degenerative disorders |
| GB2333362A (en) * | 1996-10-15 | 1999-07-21 | Imperial College | Diagnosis of spongiform encephalopathy |
| WO1999040439A1 (en) * | 1998-02-06 | 1999-08-12 | Harash Kumar Narang | Diagnosis of neuro-degenerative disorders |
| FR2827047A1 (en) * | 2001-07-03 | 2003-01-10 | Apoh Technollgies Sa | METHOD FOR SEPARATION AND / OR DETECTION AND / OR IDENTIFICATION AND / OR QUANTIFICATION OF PRION PROTEINS |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892814A (en) * | 1987-06-22 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Method for distinguishing Creutzfeldt-Jakob disease from other dementias |
-
1995
- 1995-11-28 GB GB9708663A patent/GB2308659B/en not_active Expired - Fee Related
- 1995-11-28 HU HU9702327A patent/HUT77340A/en unknown
- 1995-11-28 SK SK678-97A patent/SK67897A3/en unknown
- 1995-11-28 NZ NZ295721A patent/NZ295721A/en unknown
- 1995-11-28 CA CA002205179A patent/CA2205179A1/en not_active Abandoned
- 1995-11-28 CZ CZ971642A patent/CZ164297A3/en unknown
- 1995-11-28 AU AU39328/95A patent/AU3932895A/en not_active Abandoned
- 1995-11-28 WO PCT/GB1995/002766 patent/WO1996017249A1/en not_active Application Discontinuation
- 1995-11-28 EP EP95937124A patent/EP0795132A1/en not_active Withdrawn
-
1997
- 1997-05-22 NO NO972339A patent/NO972339D0/en unknown
- 1997-05-28 FI FI972253A patent/FI972253A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892814A (en) * | 1987-06-22 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Method for distinguishing Creutzfeldt-Jakob disease from other dementias |
Non-Patent Citations (4)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 120, no. 25, 20 June 1994, Columbus, Ohio, US; abstract no. 320660v, page 634; column 2; * |
| J.F. DIEDRICH ET AL.: "Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of Apolipoprotein E and cathepsin in astrocytes.", JOURNAL OF VIROLOGY, vol. 65, no. 9, 1 September 1991 (1991-09-01), WASHINGTON DC USA, pages 4759 - 4768, XP000567293 * |
| M.G. HARRINGTON ET AL.: "Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jacob disease.", NEW ENGLAND JOURNAL OF MEDICINE, vol. 315, no. 2, 31 July 1986 (1986-07-31), BOSTON MA USA, pages 279 - 283, XP000567332 * |
| Y. NAMBA: "Immunochemical demonstration of apolipoprotein E in cerebral amyloid deposits in Alzheimer's disease and kuru plaque amyloids in Creutzfeldt-Jacob disease.", SHINKEI KENKYU NO SHINPO, vol. 37, no. 6, TOKYO, pages 1039 - 1051 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016834A1 (en) | 1996-10-15 | 1998-04-23 | Imperial College Of Science, Technology And Medicine | Diagnosis of spongiform encephalopathy |
| GB2333362A (en) * | 1996-10-15 | 1999-07-21 | Imperial College | Diagnosis of spongiform encephalopathy |
| GB2333362B (en) * | 1996-10-15 | 2001-05-16 | Imperial College | Typing and diagnosis of spongiform encephalopathy |
| US6998231B2 (en) | 1996-10-15 | 2006-02-14 | D-Gen Limited | Typing and diagnosis of spongiform encephalopathy |
| EP0854364A1 (en) * | 1997-01-18 | 1998-07-22 | Harash Kumar Narang | Diagnosis of neuro-degenerative disorders |
| WO1999040439A1 (en) * | 1998-02-06 | 1999-08-12 | Harash Kumar Narang | Diagnosis of neuro-degenerative disorders |
| FR2827047A1 (en) * | 2001-07-03 | 2003-01-10 | Apoh Technollgies Sa | METHOD FOR SEPARATION AND / OR DETECTION AND / OR IDENTIFICATION AND / OR QUANTIFICATION OF PRION PROTEINS |
| WO2003005037A1 (en) * | 2001-07-03 | 2003-01-16 | Apoh Technologies Sa | Method for separating and/or detecting and/or identifying and/or quantifying prion proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| FI972253A (en) | 1997-07-28 |
| CZ164297A3 (en) | 1997-11-12 |
| HUT77340A (en) | 1998-03-30 |
| GB2308659A (en) | 1997-07-02 |
| AU3932895A (en) | 1996-06-19 |
| GB2308659B (en) | 1998-11-18 |
| EP0795132A1 (en) | 1997-09-17 |
| NO972339L (en) | 1997-05-22 |
| CA2205179A1 (en) | 1996-06-06 |
| FI972253A0 (en) | 1997-05-28 |
| NO972339D0 (en) | 1997-05-22 |
| NZ295721A (en) | 1999-03-29 |
| SK67897A3 (en) | 2000-02-14 |
| GB9708663D0 (en) | 1997-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU761319B2 (en) | Method and kit for extracting prion protein | |
| EP1476758B1 (en) | Detection and/or monitoring of synuclein-related diseases | |
| WO1998040748A1 (en) | Diagnosing neurologic disorders | |
| US4892814A (en) | Method for distinguishing Creutzfeldt-Jakob disease from other dementias | |
| WO1997038315A1 (en) | A method of detecting transmissible spongiform encephalopathies | |
| EP0795132A1 (en) | Spongiform encephalopathy detection methods | |
| WO1996017250A1 (en) | Spongiform encephalopathy detection methods | |
| RU2661022C2 (en) | Tropomyosin isoforms related to alzheimer's disease and moderate cognitive impairments | |
| Schmerr et al. | Capillary electrophoresis of the scrapie prion protein from sheep brain | |
| WO1998026293A1 (en) | Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms | |
| WO1998026293A9 (en) | Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms | |
| US20040175775A1 (en) | Method of detecting PrPsc in eye fluid | |
| US20030044868A1 (en) | Method for detecting prion proteins in tissue samples | |
| WO2003027631A2 (en) | Muscle sample prepared for prion assay | |
| Saunders et al. | Identification of a proteinase K resistant protein for use as an internal positive control marker in PrP Western blotting | |
| Hinsinger et al. | Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis | |
| BG64291B1 (en) | Method and kit for extracting prion protein | |
| MXPA01006875A (en) | Method and kit for extracting prion protein | |
| WO2010020037A1 (en) | The identification of disease-induced biomarkers in the urine of bse infected cattle | |
| ZA200105304B (en) | Method and kit for extracting prion protein. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1995937124 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2205179 Country of ref document: CA Kind code of ref document: A Ref document number: 2205179 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 295721 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV1997-1642 Country of ref document: CZ Ref document number: 972253 Country of ref document: FI |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 67897 Country of ref document: SK |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 1995937124 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: PV1997-1642 Country of ref document: CZ |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1995937124 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV1997-1642 Country of ref document: CZ |